Monday - Friday, 6:00 - 7:00 PM ET AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the company develop medicines faster, identify promising drug targets, and improve the odds of ...

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning. By ...

Trying to get medicine approved by the US Food and Drug Administration often feels like buying an expensive lottery ticket, with the uncertain prospect of a reward years away. It takes about a decade ...

Researcher Jeffrey L. Cummings M.D., ScD, from the Kirk Kerkorian School of Medicine at UNLV, has released his annual report on the global effort to find a cure for Alzheimer's. The work is published ...

The National Drug Control Strategy is prepared biennially by the Office of National Drug Control Policy. This document provides a strategic roadmap for the Administration to continue dismantling the ...

Eli Lilly LLY-1.21%decrease; down pointing triangle Chief Executive Dave Ricks was on stage with Nvidia NVDA 2.95%increase; up pointing triangle founder Jensen Huang earlier this year in San Francisco ...

AWS has now unveiled Amazon Bio Discovery, an AI platform that grants researchers direct access to a broad library of biological foundation models that can be fine-tuned for specific use cases in drug ...

Insilico Medicine Cayman TopCo’s shares jumped on Monday after it struck an artificial intelligence-driven drug development deal with Eli Lilly & Co. worth up to $2.75 billion. Shares of the Hong Kong ...

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.

Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than toxic chemicals—a discovery that could accelerate and improve how medicines ...

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) The following represents ...

Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 9th Annual Drug Discovery & Development Virtual Event on February ...